Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.

Breast cancer research and treatment - 1 Jan 2011

Thompson Alastair M, Johnson Andrea, Quinlan Philip, Hillman Grantland, Fontecha Marcel, Bray Susan E, Purdie Colin A, Jordan Lee B, Ferraldeschi Roberta, Latif Ayshe, Hadfield Kirsten D, Clarke Robert B, Ashcroft Linda, Evans D Gareth, Howell Anthony, Nikoloff Michele, Lawrence Jeffrey, Newman William G

Abstract excerpt

The association between CYP2D6 genotype and outcome in breast cancer patients treated with adjuvant tamoxifen remains controversial. We assessed the influence of comprehensive versus limited CYP2D6 genotype in the context of tamoxifen adherence and co-medication in a large cohort of 618 patients....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6 Inhibitors

Share to Disease-Free Survival

Share to Drug Interactions

Share to Medication Adherence

Share to Proportional Hazards Models

Share to Tamoxifen

Source

Identifiers

PMID: 20809362
DOI: 10.1007/s10549-010-1139-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20809362-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.PMID 20809362Read ↗

CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.Semantic proximity Read ↗

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.Semantic proximity Read ↗

CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.Semantic proximity Read ↗

Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?Semantic proximity Read ↗

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.Semantic proximity Read ↗

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.Semantic proximity Read ↗

CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients.Semantic proximity Read ↗

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.Semantic proximity Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

Genotype-guided tamoxifen therapy: time to pause for reflection?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.